Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage

Table 2 Changes in the FIB-4 index during the study period

		ALT ≦ ULN	ULN < ALT ≦ 2×ULN	2×ULN < ALT	P-value for changes among the groups
Pemafibrate	Baseline	1.18 (0.92, 1.61)	1.42 (0.95, 1.85)	1.76 (1.10, 2.01)
Pemafibrate	Changes	0.02 (− 0.04 to 0.09)	0.07 (− 0.09 to 0.12)	−0.05 (− 0.22 to − 0.02) *†	0.036
Control	Baseline	1.41 (0.97, 1.92)	1.23 (0.95, 1.70)	1.26 (0.70, 1.94)
Control	Changes	0.04 (− 0.03 to 0.10)	0.06 (− 0.01 to 0.10)	0.02 (− 0.19 to 0.20)	0.884

Values are the median (25, 75%) or median change (95% CI). *p < 0.05 vs. baseline (Mann-Whitney U-test), †p < 0.05 vs. ALT ≤ ULN group (Dunn’s test). ALT, alanine aminotransaminase; ULN, upper limit normal

ISSN: 1758-5996